Search
for
Sort by
Research 241–270 of 1000+
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- Serum vitamin D level is related to disease severity in pediatric alopecia areata
- Evaluation of Serum Homocysteine, High-Sensitivity CRP, and RBC Folate in Patients with Alopecia Areata
- Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
- Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes
- Extensive alopecia areata: Not necessarily recalcitrant to therapy!
- Rethinking the classification of alopecia areata
- Assessment of Vitamin D Level in Patients of Alopecia Areata
- Successful treatment of resistant alopecia areata with a phototoxic dose of ultraviolet A after topical 8‐methoxypsoralen application
- Experience with oral tofacitinib in severe alopecia areata with different clinical responses
- Response of alopecia areata of the beard to oral tofacitinib
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege
- Weekly azathioprine pulse versus betamethasone oral mini-pulse in the treatment of moderate-to-severe alopecia areata
- Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
- Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Wharton’s jelly-derived mesenchymal stem cells in the treatment of four patients with alopecia areata
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Study on Serum Vitamin D in Alopecia Areata Patients
- An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
- European expert consensus statement on the systemic treatment of alopecia areata
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- Serum interleukin-37 and its gene polymorphism (rs3811047) in Egyptian patients with alopecia areata
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- The Relationship Between ABO And Rh Blood Groups With Alopecia Areata
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- Not just thinning: A case of alopecia universalis after mild COVID-19
- Cellular retinol‐binding protein‐1 expression increases with increasing clinical severity of alopecia areata